Toll Free: 1-888-928-9744

Peanut Allergy - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 92 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Peanut Allergy - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2016, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 3, 9 and 5 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively for Peanut Allergy.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Peanut Allergy Overview 8 Therapeutics Development 9 Pipeline Products for Peanut Allergy - Overview 9 Pipeline Products for Peanut Allergy - Comparative Analysis 10 Peanut Allergy - Therapeutics under Development by Companies 11 Peanut Allergy - Therapeutics under Investigation by Universities/Institutes 13 Peanut Allergy - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Peanut Allergy - Products under Development by Companies 17 Peanut Allergy - Products under Investigation by Universities/Institutes 18 Peanut Allergy - Companies Involved in Therapeutics Development 19 Adverum Biotechnologies, Inc. 19 Aimmune Therapeutics, Inc. 20 Alfacyte Ltd 21 Allergy Therapeutics Plc 22 AnaptysBio, Inc. 23 Aravax Pty Ltd 24 Array BioPharma Inc. 25 ASIT biotech s.a. 26 Astellas Pharma Inc. 27 BioLingus AG 28 DBV Technologies S.A. 29 HAL Allergy BV 30 Sanofi 31 Peanut Allergy - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 aldesleukin - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Allergen for Peanut Allergy - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Allergen for Peanut Allergy - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 Allergen for Peanut Allergy - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 ANB-020 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ANN-004 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 AR-101 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 AR-460770 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 ASP-0892 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 DBV-712 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 HALMPE-1 - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 INT-301 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Peanut Allergy Vaccine - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 PER-1080 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 pnut-ASIT - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Polyvac Peanut - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 Recombinant Protein for Peanut Allergy - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 SCV-204 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 SCV-209 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Vaccine for Peanut Allergy - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 VTC-064 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Peanut Allergy - Dormant Projects 74 Peanut Allergy - Discontinued Products 75 Peanut Allergy - Product Development Milestones 76 Featured News & Press Releases 76 Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results 76 Oct 02, 2016: Immunomic Therapeutics Scientist Presenting at International Society for Vaccines Annual Congress 76 Sep 28, 2016: Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development 76 Sep 20, 2016: Aimmune Therapeutics Completes and Exceeds North American Enrollment Target Ahead of Schedule in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy; Company Accelerates Plans for Real-World Experience Study in the U.S. 77 Aug 18, 2016: Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children 78 Aug 01, 2016: DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy 79 Jul 05, 2016: DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer 81 Jun 27, 2016: DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children 81 Jun 21, 2016: Aimmune Therapeutics Appoints Daniel Adelman, M.D., as Chief Medical Officer 82 Jun 21, 2016: DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere 83 Jun 15, 2016: DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression 84 Jun 13, 2016: Aimmune Therapeutics Announces Phase 2 Extended Maintenance Data Supporting Safety and Tolerability Profile of AR101 for Peanut Allergy 85 Jun 07, 2016: Aimmune Therapeutics Announces Late-Breaker Presentation at the European Academy of Allergy and Clinical Immunology Congress 2016 86 Jun 07, 2016: DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board 87 Jun 01, 2016: DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies 88 Appendix 91 Methodology 91 Coverage 91 Secondary Research 91 Primary Research 91 Expert Panel Validation 91 Contact Us 91 Disclaimer 92
List of Tables
Number of Products under Development for Peanut Allergy, H2 2016 9 Number of Products under Development for Peanut Allergy - Comparative Analysis, H2 2016 10 Number of Products under Development by Companies, H2 2016 12 Number of Products under Investigation by Universities/Institutes, H2 2016 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Peanut Allergy - Pipeline by Adverum Biotechnologies, Inc., H2 2016 19 Peanut Allergy - Pipeline by Aimmune Therapeutics, Inc., H2 2016 20 Peanut Allergy - Pipeline by Alfacyte Ltd, H2 2016 21 Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H2 2016 22 Peanut Allergy - Pipeline by AnaptysBio, Inc., H2 2016 23 Peanut Allergy - Pipeline by Aravax Pty Ltd, H2 2016 24 Peanut Allergy - Pipeline by Array BioPharma Inc., H2 2016 25 Peanut Allergy - Pipeline by ASIT biotech s.a., H2 2016 26 Peanut Allergy - Pipeline by Astellas Pharma Inc., H2 2016 27 Peanut Allergy - Pipeline by BioLingus AG, H2 2016 28 Peanut Allergy - Pipeline by DBV Technologies S.A., H2 2016 29 Peanut Allergy - Pipeline by HAL Allergy BV, H2 2016 30 Peanut Allergy - Pipeline by Sanofi, H2 2016 31 Assessment by Monotherapy Products, H2 2016 32 Number of Products by Stage and Target, H2 2016 34 Number of Products by Stage and Mechanism of Action, H2 2016 36 Number of Products by Stage and Route of Administration, H2 2016 38 Number of Products by Stage and Molecule Type, H2 2016 40 Peanut Allergy - Dormant Projects, H2 2016 74 Peanut Allergy - Discontinued Products, H2 2016 75



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify